# An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction Cancer

> **NCT02743494** · PHASE3 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 794 (actual)

## Conditions studied

- Advanced Cancer

## Interventions

- **DRUG:** Nivolumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02743494
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07-14
- **Primary completion:** 2020-05-12
- **Final completion:** 2024-11-07
- **Target enrollment:** 794 (ACTUAL)
- **Last updated:** 2025-11-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02743494

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02743494, "An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02743494. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*